ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
17.87
-0.05 (-0.28%)
At close: Jul 25, 2025, 4:00 PM
18.22
+0.35 (1.96%)
After-hours: Jul 25, 2025, 7:04 PM EDT
ARS Pharmaceuticals Revenue
ARS Pharmaceuticals had revenue of $7.97M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $97.12M, up 971,120.00% year-over-year. In the year 2024, ARS Pharmaceuticals had annual revenue of $89.15M with 297,063.33% growth.
Revenue (ttm)
$97.12M
Revenue Growth
+971,120.00%
P/S Ratio
17.96
Revenue / Employee
$607,013
Employees
160
Market Cap
1.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 89.15M | 89.12M | 297,063.33% |
| Dec 31, 2023 | 30.00K | -1.29M | -97.72% |
| Dec 31, 2022 | 1.32M | -4.19M | -76.10% |
| Dec 31, 2021 | 5.51M | -12.33M | -69.13% |
| Dec 31, 2020 | 17.84M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| Novartis AG | 55.19B |
| AstraZeneca | 54.98B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
SPRY News
- 7 days ago - EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray) - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians - GlobeNewsWire
- 3 months ago - ARS Pharmaceuticals Has A Blockbuster Candidate - Seeking Alpha